普拉瑞克 | 134457-28-6

• 分子结构分类: 有机化合物 - 有机聚合物 - 多肽
• 中文名称: 普拉瑞克
• 英文名称: [Ac-D-2Nal¹, D-4Cpa², D-3Pal³, 4Aph(Atz)⁵, D-4Aph(Atz)⁶, ILys⁸, D-Ala¹⁰]gonadotropin-releasing hormone
• 英文别名: 1,DCpa²,DPal³,Aph(atz)⁵,DAph(atz)⁶,ILys⁸,DAla¹⁰>GnRH；azaline B；[Ac-DNal¹,DCpa²,DPal³,Aph(atz)⁵,DAph(atz)⁶,ILys⁸,DAla¹⁰]GnRH；(2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-[4-[(5-amino-4H-1,2,4-triazol-3-yl)amino]phenyl]propanoyl]amino]-3-[4-[(5-amino-1H-1,2,4-triazol-3-yl)amino]phenyl]propanoyl]amino]-4-methylpentanoyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
• CAS: 134457-28-6
• 化学式: C₈₀H₁₀₂ClN₂₃O₁₂
• 分子量: 1613.29
• InChiKey: VLGKQBGBPIVGBX-ZVSGBDDQSA-N

物化性质

• 密度：
  1.348±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  116
• 可旋转键数：
  42
• 环数：
  9.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  530
• 氢给体数：
  18
• 氢受体数：
  22

反应信息

• 作为产物：
  描述：

  N-氰基羰亚胺二苯基酯 、 alkaline earth salt of/the/ methylsulfuric acid 生成 普拉瑞克
  参考文献：
  名称：

  Novel gonadotropin-releasing hormone antagonists: peptides incorporating modified N.omega.-cyanoguanidino moieties

  摘要：

  In order to minimize the deleterious effects of histamine release resulting from the administration to rats and humans of some potent gonadotropin-releasing hormone (GnRH) antagonists, various arginine residues were replaced with the less basic N-omega-cyano-N-omega'-alkyl- or -arylhomoarginine, -arginine, or -p-aminophenylalanine and N-omega-triazolyllysine, -ornithine or -p-aminophenylalanine residues in active analogues. These novel analogues were synthesized on a solid-phase support via a two-step modification of the N-omega-NH2 of lysine, ornithine, or p-aminophenylalanine residues in otherwise protected resin bound peptides. Most analogues were tested in the rat antiovulatory assay (AOA) and three in vitro assays: a pituitary cell culture assay, a binding assay to pituitary cell membranes, and a histamine release assay. Introduction of the cyanoguanidino and N-omega-triazolyl moieties into GnRH analogues yielded several water-soluble antagonists which showed a desirable therapeutic ratio (low histamine release activity to high in vivo potency). Among them, ''Azaline'' (10, [Ac-DNal1,DCpa2,DPal3,Lys5(atz),DLys6(atz),ILys8,DAla10]GnRH), inhibited ovulation in the rat by 90% at 2-mu-g/rat with an ED50 in the in vitro histamine release assay comparable to that of GnRH itself.

  DOI：

  10.1021/jm00112a013

文献信息

• [EN] METABOLITES OF SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF<br/>[FR] MÉTABOLITES DE MODULATEURS DE RÉCEPTEUR ANDROGÈNE SÉLECTIFS ET PROCÉDÉS D'UTILISATION DE CEUX-CI
  申请人：GTX INC

  公开号：WO2009155481A1

  公开（公告）日：2009-12-23

  This invention provides metabolites of SARM compounds including inter alia glucuronidated metabolites and uses thereof in treating a variety of diseases or conditions in a subject, including, inter alia, muscle wasting disease and/or disorder, a bone related disease and/or disorder, metabolic syndrome, diabetes and associated diseases, and others.

  这项发明提供了SARM化合物的代谢产物，包括葡萄糖醛酸酯化合物等，并利用它们在治疗受试者中的多种疾病或症状，包括但不限于肌肉消耗疾病和/或紊乱、与骨相关的疾病和/或紊乱、代谢综合征、糖尿病及相关疾病等。
• SARMS AND METHOD OF USE THEREOF
  申请人：Dalton James T.

  公开号：US20100249228A1

  公开（公告）日：2010-09-30

  This invention is directed to a feed composition and method of affecting the carcass composition by increasing the lean mass, reducing the fat mass, and/or reducing the percent fat mass comprising SARM compounds.

  本发明涉及一种饲料组合物和方法，通过增加瘦肉含量、减少脂肪含量和/或减少脂肪百分比含量，其中包括SARM化合物，以影响肉体组成。
• SELECTIVE ANDROGEN RECEPTOR MODULATORS FOR TREATING DIABETES
  申请人：Dalton James T.

  公开号：US20130034562A1

  公开（公告）日：2013-02-07

  This invention provides use of a SARM compound or a composition comprising the same in treating and preventing muscle wasting in patients with non-small cell lung cancer (NSCLC); treating pre-cachexia or early cachexia (preventing muscle wasting in a cancer patient); treating and preventing loss of physical function due to cancer or cancer therapy; increase of physical function; and increasing survival in a patient with NSCLC, wherein the patients are subjected to cancer therapy.

  本发明提供了一种使用SARM化合物或包含该化合物的组合物来治疗和预防非小细胞肺癌（NSCLC）患者的肌肉消耗；治疗癌症患者的早期消瘦或恶病质（预防肌肉消耗）；治疗和预防由癌症或癌症治疗引起的身体机能丧失；增加身体机能；并提高NSCLC患者的生存率，其中患者接受癌症治疗。
• SELECTIVE ANDROGEN RECEPTOR MODULATOR AND METHODS OF USE THEREOF
  申请人：UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION

  公开号：US20160166530A1

  公开（公告）日：2016-06-16

  This invention provides substituted acylanilide compounds and uses thereof in treating a variety of diseases or conditions in a subject including, inter alia, a muscle wasting disease and/or disorder such as Duchenne muscular dystrophy or Becker muscular dystrophy.

  本发明提供了取代的酰基苯胺化合物及其在治疗受试者中的各种疾病或病况中的应用，包括但不限于肌肉消耗病和/或疾病，如杜氏肌肉萎缩症或贝克肌肉萎缩症。
• Nuclear receptor binding agents
  申请人：Dalton James T.

  公开号：US20090030036A1

  公开（公告）日：2009-01-29

  The present invention relates to a novel class of nuclear receptor binding agents (NRBAs). The NRBAs are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including prevention and treatment of cancers such as prostate and breast cancer, osteoporosis, hormone-related diseases, inflammatory diseases, oxidative stress related disorders such as Parkinson's and stroke, neurological disorders, ophthalamic disorders, cardiovascular disease, and obesity.

  本发明涉及一种新型的核受体结合剂（NRBAs）。这些NRBAs适用于预防和/或治疗各种疾病和病症，包括预防和治疗癌症（如前列腺癌和乳腺癌）、骨质疏松症、激素相关疾病、炎症性疾病、氧化应激相关疾病（如帕金森病和中风）、神经系统疾病、眼科疾病、心血管疾病和肥胖症。